RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy
- PMID: 36919837
- PMCID: PMC10152175
- DOI: 10.5152/tjg.2023.237002
RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy
Conflict of interest statement
References
-
- European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370 398. ( 10.1016/j.jhep.2017.03.021) - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources